Cancer Immunology, Immunotherapy

, Volume 36, Issue 6, pp 357–363 | Cite as

Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody

  • Yoshitane Dohi
  • Shoji Sunada
  • Masahiro Aoki
  • Akira Moriguchi
  • Masafumi Okabayashi
  • Masahiko Miyata
  • Hikaru Matsuda
Original articles

Abstract

The possibility of in vivo removal of metastatic tumour cells from lymph nodes by local intradermal administration of an anti-CD3 monoclonal antibody (mAb) was examined. Murine tumour cells in the lymph nodes were completely eradicated by intradermal injections of the mAb. This treatment was effective for removal of Lewis lung cancer cells from lymph nodes, but not for removal of subcutaneous tumours of this cell line. This treatment induced in vivo cytotoxicity in the regional lymph nodes against the syngeneic tumour cells. The following in vitro studies suggested that the cytotoxicity was probably mediated mainly by CD4+ T cells, with slight participation of CD8+ T cells. Normal lymph node and spleen cells showed cytotoxicity after in vitro incubation with the mAb for 2 days. Cell sorting with a fluoresceinactivated cell sorter showed that CD4+ T cells developed during the incubation to lyse syngeneic tumor cells directly by themselves, macrophages not being involved in this tumour cell lysis. The lytic activity was detected in the cellular fractions, but not in the culture supernatants of these T cells. Furthermore, it was completely blocked by specific antiserum for tumour necrosis factor-α (TNFα). An immunoprecipitation study revealed that these T cells expressed TNFα molecules of 26 kDa, but not of 17 kDa, suggesting that tumour cell lysis was caused by membraneintegrated TNFα molecules. These results strongly suggest that local administration of anti-CD3 antibody is a very effective and appropriate procedure for eradication of metastatic tumour cells from regional lymph nodes.

Key words

Lymph node metastasis Metastatic tumour Anti-CD3 mAb CD4+ CTL TNFα 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davignon D, Marz E, Reynolds T, Kurzinger K, Springer TA (1981) Lymphocyte function-associated antigen-1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing. Proc Natl Acad Sci USA 78: 4535Google Scholar
  2. 2.
    Ellenhorn JDI, Hirsh R, Schreiber H, Bluestone JA (1988) In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science 242: 569Google Scholar
  3. 3.
    Ellenhorn JDI, Schreiber H, Bluestone JA (1990) Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice. J Immunol 144: 2840Google Scholar
  4. 4.
    Fehsel K, Kolb-Bachofen V, Kolb H (1991) Analysis of TNF-α induced DNA strand breaks at the single cell level. Am J Pathol 139: 251Google Scholar
  5. 5.
    Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone JA, Bach JF, Chatenoud L (1990) Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 20: 509Google Scholar
  6. 6.
    Grogg D, Hahn S, Erb P (1992) CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC). III. CD4+ cytotoxic T cells induce apoptosis of APC. Eur J Immunol 22: 267Google Scholar
  7. 7.
    Hohmann HP, Remy R, Brockhaus M, van Loon APGM (1989) Two different cell types have different major receptors for human tumor necrosis factor (TNFα). J Biol Chem 264: 14 927Google Scholar
  8. 8.
    Jaffers GJ, Fuller TC, Cosimi AB, Russel PS, Winn HJ, Colvin RB (1986) Monoclonal antibody therapy. Anti-idiotypic and non-antiidiotypic antibodies to OKT3 arising despite intense immuno-suppression. Transplantation 41: 572Google Scholar
  9. 9.
    Kawasaki A, Sinkai Y, Kuwana Y, Furuya A, Iigo Y, Hanai N, Itoh S, Yagita H, Okumura K (1990) Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cells. Intern Immunol 2: 677Google Scholar
  10. 10.
    Kliegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramification for the complex physiology of TNF. Cell 53: 45Google Scholar
  11. 11.
    Laemmli EK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680Google Scholar
  12. 12.
    Leo O, Foo M, Sachs D, Samelson LE, Bluestone JA (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84: 1374Google Scholar
  13. 13.
    Liu AY, Miskovsky EP, Stanhope PE, Siliciano RF (1992) Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-α by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-α-independent cytolytic mechanism. J Immunol 148: 3789Google Scholar
  14. 14.
    Lotzova E, Savary CA, Herberman RB, McCredie KB, Keating MJ, Freireich EJ (1987) Augmentation of antileukemia lytic activity by OKT 3 monoclonal antibody: synergism of OKT3 and interleukin-2. Nat Immun Cell Growth Regul 6: 219Google Scholar
  15. 15.
    Munker R, Dipersio J, Koeffler HP (1987) Tumor necrosis factor: Receptors on hematopoietic cells. Blood 70: 1730Google Scholar
  16. 16.
    Nishimura T, Nakamura Y, Takeuchi Y, Tokuda Y, Iwasawa M, Kawasaki A, Okumura K, Habu S (1992) Generation, propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. J Immunol 148: 285Google Scholar
  17. 17.
    Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH (1987) Longterm growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, and interferon-gamma and -beta. J Immunol 138: 2728Google Scholar
  18. 18.
    Robaye B, Mossemans R, Fiers W, Dumont JE, Galant P (1991) Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol 138: 447Google Scholar
  19. 19.
    Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carsswell EA, Old LJ (1985) High affinity binding of125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors. J Exp Med 162: 10 999Google Scholar
  20. 20.
    Shaw S, Luce GEG, Quinones R, Gress RE, Springer TA, Sanders ME (1986) Two antigen-independent adhesion pathways used by human cytotoxic T cell clones. Nature 323: 262Google Scholar
  21. 21.
    Shinkai Y, Takio K, Okumura K (1983) Homology of perfolin to ninth component of complement (C9). Nature 334: 525Google Scholar
  22. 22.
    Tsujimoto M, Yip YK, Vilcek J (1985) Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci USA 82: 7626Google Scholar
  23. 23.
    Yonehara S, Yonehara M (1989) A cell-killing monoclonal antibody (Anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Yoshitane Dohi
    • 1
  • Shoji Sunada
    • 1
    • 2
  • Masahiro Aoki
    • 1
  • Akira Moriguchi
    • 1
    • 2
  • Masafumi Okabayashi
    • 1
  • Masahiko Miyata
    • 2
  • Hikaru Matsuda
    • 2
  1. 1.Department of BacteriologyOsaka University Medical SchoolSuita OsakaJapan
  2. 2.First Department of SurgeryOsaka University Medical SchoolOsakaJapan

Personalised recommendations